Delphi Automotive (DLPH) Still Offering Growth in 2013

Page 1 of 2

Delphi Automotive PLC (NYSE:DLPH) is a vehicle components manufacturer that provides electrical and thermal technology for autos. Although Delphi is already up over 75% year to date, we still see room for growth in 2013.

Delphi’s 3Q EPS results came in at $0.84 versus $0.72 for 3Q 2011. Strong future performance is expected to come from its recent acquisition of FCI Group’s motorized vehicles division (MVL). The auto company plans to spend $250 million in restructuring costs to integrate MVL, but the savings will be upwards of $80 million for 2013 alone. Billionaire John Paulson is one of Delphi’s biggest investors, owning over 25 million shares (check out John Paulson’s picks).

PAULSON & CO

The chief fundamental driver for the company will be a rise in auto sales. The current average age of vehicles on the road is pushing eleven years. Additionally, MVL’sĀ pre-synergistic EBITDA contribution of $130 million, which is expected to add $0.22 to 2013 EPS, will help out in the short term.

From a valuation standpoint, Delphi is one of the cheapest stocks in the industry at only 8x forward earnings and 7x cash flow. It is hard to see why the auto parts company trades at a such a discount to its peers when it leads in so many areas – including return on equity (60%), 5-year expected EPS growth (18% CAGR) and EBITDA margin (14%). Placing the peer average forward P/E (11x) on Delphi’s 2013 EPS estimates suggests upside of 25% over the next 12 months.

Notable competitorĀ Visteon Corporation (NYSE:VC) supplies climate control and lighting systems for use in autos. The company is on the high-end of the industry’s valuation spectrum at 80x earnings. We tend to agree with many hedge fund investors that Visteon could unlock shareholder value by spinning off its non-core assets and focusing on its climate control business. Following a 40% stake increase, Visteon now calls billionaire Steven Cohen as one of its top investors (check out Steven Cohen’s key picks).

Who’s the best of the rest?

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!